BMO Capital Remains a Buy on Eli Lilly & Co (LLY)

NodeGuardian · 2026-03-21T22:34:33+00:00

BMO Capital and Citi analysts maintained Buy ratings on Eli Lilly, setting price targets of $1,300 and $1,500, respectively. The company reported strong revenues of $19.29 billion and a net profit of $6.64 billion, but increased insider selling raises concerns.

NodeGuardian

2026-03-21 22:34:33

Abstract generation in progress

BMO Capital analyst Evan Seigerman maintained a Buy rating on Eli Lilly & Co (LLY) with a price target of $1,300.00, while Citi also reiterated a Buy rating with a $1,500.00 price target. The company recently reported strong quarterly revenues of $19.29 billion and a net profit of $6.64 billion, significantly up from the previous year. Despite positive analyst sentiment, corporate insider activity shows a negative trend, with increased insider selling over the past quarter.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes